These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16806606)

  • 1. Vaccination confers significant protection of sheep against infection with a virulent United Kingdom strain of Corynebacterium pseudotuberculosis.
    Fontaine MC; Baird G; Connor KM; Rudge K; Sales J; Donachie W
    Vaccine; 2006 Aug; 24(33-34):5986-96. PubMed ID: 16806606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of an ovine caseous lymphadenitis vaccine formulated using a genetically inactive form of the Corynebacterium pseudotuberculosis phospholipase D.
    Hodgson AL; Carter K; Tachedjian M; Krywult J; Corner LA; McColl M; Cameron A
    Vaccine; 1999 Feb; 17(7-8):802-8. PubMed ID: 10067685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Corynebacterium pseudotuberculosis recombinant proteins rCP09720 or rCP01850 with rPLD as immunogens in caseous lymphadenitis immunoprophylaxis.
    Silva MTO; Bezerra FSB; de Pinho RB; Begnini KR; Seixas FK; Collares T; Portela RD; Azevedo V; Dellagostin O; Borsuk S
    Vaccine; 2018 Jan; 36(1):74-83. PubMed ID: 29174312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunisation against ovine caseous lymphadenitis: comparison of Corynebacterium pseudotuberculosis vaccines with and without bacterial cells.
    Eggleton DG; Middleton HD; Doidge CV; Minty DW
    Aust Vet J; 1991 Oct; 68(10):317-9. PubMed ID: 1755781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Corynebacterium pseudotuberculosis bacterin for the immunologic protection of sheep against development of caseous lymphadenitis.
    LeaMaster BR; Shen DT; Gorham JR; Leathers CW; Wells HD
    Am J Vet Res; 1987 May; 48(5):869-72. PubMed ID: 3592392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired immunity after primary caseous lymphadenitis in sheep.
    Pépin M; Pardon P; Marly J; Lantier F; Arrigo JL
    Am J Vet Res; 1993 Jun; 54(6):873-7. PubMed ID: 8323055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunisation against ovine caseous lymphadenitis: efficacy of monocomponent Corynebacterium pseudotuberculosis toxoid vaccine and combined clostridial-corynebacterial vaccines.
    Eggleton DG; Doidge CV; Middleton HD; Minty DW
    Aust Vet J; 1991 Oct; 68(10):320-1. PubMed ID: 1755782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological response of vaccinated sheep after challenge with Corynebacterium pseudotuberculosis.
    Sutherland SS; Ellis TM; Paton MJ; Mercy AR
    Aust Vet J; 1992 Jul; 69(7):168-9. PubMed ID: 1445082
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunisation against ovine caseous lymphadenitis: correlation between Corynebacterium pseudotuberculosis toxoid content and protective efficacy in combined clostridial-corynebacterial vaccines.
    Eggleton DG; Haynes JA; Middleton HD; Cox JC
    Aust Vet J; 1991 Oct; 68(10):322-5. PubMed ID: 1755783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of sheep against caseous lymphadenitis by use of a single oral dose of live recombinant Corynebacterium pseudotuberculosis.
    Hodgson AL; Tachedjian M; Corner LA; Radford AJ
    Infect Immun; 1994 Dec; 62(12):5275-80. PubMed ID: 7960105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of an ELISA test to detect antibodies in vaccinated sheep or infected Corynebacterium pseudotuberculosis].
    Solanet JJ; Malena R; Estein SM; Estevao Belchior S; Paolicchi FA
    Rev Argent Microbiol; 2011; 43(1):9-17. PubMed ID: 21491060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a commercially available vaccine against Corynebacterium pseudotuberculosis for use in sheep.
    Piontkowski MD; Shivvers DW
    J Am Vet Med Assoc; 1998 Jun; 212(11):1765-8. PubMed ID: 9621886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A field trial to evaluate a whole cell vaccine for the prevention of caseous lymphadenitis in sheep and goat flocks.
    Menzies PI; Muckle CA; Brogden KA; Robinson L
    Can J Vet Res; 1991 Oct; 55(4):362-6. PubMed ID: 1790493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of caseous lymphadenitis and usage of caseous lymphadenitis vaccines in sheep flocks.
    Paton MW; Walker SB; Rose IR; Watt GF
    Aust Vet J; 2003; 81(1-2):91-5. PubMed ID: 15084020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of caseous lymphadenitis.
    Windsor PA
    Vet Clin North Am Food Anim Pract; 2011 Mar; 27(1):193-202. PubMed ID: 21215903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigens of Corynebacterium pseudotuberculosis and prospects for vaccine development.
    Dorella FA; Pacheco LG; Seyffert N; Portela RW; Meyer R; Miyoshi A; Azevedo V
    Expert Rev Vaccines; 2009 Feb; 8(2):205-13. PubMed ID: 19196200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep.
    Chaplin PJ; De Rose R; Boyle JS; McWaters P; Kelly J; Tennent JM; Lew AM; Scheerlinck JP
    Infect Immun; 1999 Dec; 67(12):6434-8. PubMed ID: 10569760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spread of Corynebacterium pseudotuberculosis infection to unvaccinated and vaccinated sheep.
    Paton MW; Sutherland SS; Rose IR; Hart RA; Mercy AR; Ellis TM
    Aust Vet J; 1995 Jul; 72(7):266-9. PubMed ID: 8534231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence of caseous lymphadenitis in Alberta sheep and assessment of impact by vaccination with commercial and experimental vaccines.
    Stanford K; Brogden KA; McClelland LA; Kozub GC; Audibert F
    Can J Vet Res; 1998 Jan; 62(1):38-43. PubMed ID: 9442938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene.
    Tachedjian M; Krywult J; Moore RJ; Hodgson AL
    Vaccine; 1995 Dec; 13(18):1785-92. PubMed ID: 8701594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.